Emyria (ASX:EMD)

Interim Clinical Results for PTSD Program Emyria (ASX:EMD) has released compelling insight into the progress of its Post-Traumatic Stress Disorder (PTSD) Program, including interim clinical results for the first eight patients. Key highlights include: ▶ Interim analysis of the first eight patients completing Emyria's MDMA-assisted therapy (MDMA-AT) PTSD program shows all patients achieved substantial improvement in PTSD symptoms, with a clinically and statistically significant average reduction of 33 points in PCL-5 scores. ▶ All patients reported substantial gains in quality of life. ▶ Emyria continues to evolve its leading care programs by actively collecting and applying Real-World Data, setting the pace and standards for PTSD care globally. ▶ Plans are underway to sustainably expand these programs, in close partnership with private hospitals and third-party payers. These results will be shared in detail by Emyria’s Lead Psychiatrist, Dr Jon Laugharne, at the WA Branch Conference of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) this weekend on 6 and 7 September. See the ASX release 👉 https://lnkd.in/gAHaSTNJ   $EMD #EMD #ASX #MDMATherapyResearch #innovation #biotech #mentalhealth #health

Emyria (ASX:EMD) CEO and MD, Dr Michael Winlo, was thrilled to address participants at this weekend's Bellberry HREC Education event in Adelaide. His presentation, "MDMA: Opportunities & Challenges," explored the unique landscape of MDMA research – both in Australia and in a global context As a leading global provider of MDMA research and therapy delivery, Emyria is committed to generating robust clinical evidence and developing improved care models and drug therapies for complex mental health conditions. We recognise the vital role Human Research Ethics Committees (HRECs) play in ensuring the ethical conduct of research, particularly in emerging fields like MDMA-assisted therapy. We look forward to contributing to the ongoing conversation about the responsible advancement of MDMA research. $EMD #Emyria #mentalhealth #PTSD #research #ethics #MDMAResearch

🗞 AFR Feature Story    The US Food and Drug Administration (FDA) is calling for more data before approving MDMA for the treatment of post-traumatic stress disorder (PTSD) – this is not a vote against MDMA, it is a call for more robust data. A critical distinction to make. With no new PTSD drugs approved in over 20 years, this decision simply underscores the urgent need for thorough, follow-up research. Emyria (ASX:EMD)’s proven success in delivering medication-assisted therapies under Australia’s rigorous regulatory framework demonstrates our readiness. We are laser-focused on patient outcomes and growth via our unique, evidence-generating care model and remain deeply committed to advancing promising new treatments – regardless of the FDA’s timelines. Today, we were highlighted in a full-page feature in the The Australian Financial Review by Health Editor Michael Smith titled “Psychedelics as a serious investment? These billionaires think so”. The story explores, in detail, the investment opportunity and clinical impact of key players who are pioneering novel treatments for mental health conditions – including commentary from Emyria CEO and MD, Dr Michael Winlo, where he discusses the Company's ongoing commitment to pioneering treatments and shaping the future of mental health care. By operating in Australia, a jurisdiction where this therapy is legally allowed, Emyria already has a distinct global advantage, and now a profound opportunity, to positively impact patient lives and gather the robust data required to advance this field.  Read the article here 👉 https://bit.ly/EMD_AFR   #Health #mental #MDMA #psychedlics #innovation #research

📊 Quarterly Report   Emyria (ASX:EMD) has today released its Quarterly report for the period ending 30 June 2024. Key highlights for the period include: ✅ Opening of first Empax Centre, Emyria’s new, state-of-the-art facility dedicated to the delivery and development of new treatments for mental health, including post traumatic stress disorder (PTSD). ✅ First female Authorised Prescriber for MDMA-assisted therapy in Australia and enhancing our capacity for trials and patient care, aligning with our clinical service expansion initiatives. ✅ Appointment of new General Manager to drive growth ✅ MDMA-AT for First Responders Research Agreement with charity Reach Wellness ✅ Empax Centre was selected as a key site for the global "IMPACT-2" trial on PTSD. ✅ Strong Revenue Growth for Mental Health Programs with over $1m of clinical billings in the June Quarter ✅ Successful Placement of $2.3 million with significant Director participation Emyria’s Managing Director, Dr. Michael Winlo, commented: “Emyria's June quarter has been a period of remarkable growth supported by the opening of our new Empax Centre, confirmation of Australia’s first female Authorised Prescriber and a significant increase in our mental health service revenues. “With substantial financial support, we are well-positioned to continue expanding patient access to high-quality mental health care and innovative treatments. Specifically, we are driving improved patient access through our own therapy programs, clinical research collaborations, site expansion initiatives and payer engagement.” See today’s ASX release 👉 https://lnkd.in/gmCjjrDA    $EMD #EMD #ASX #MDMATherapyResearch #innovation #biotech #mentalhealth #health

➖ New grant ➖ Emyria (ASX:EMD) is pleased to announce that it has received, in partnership with the The University of Western Australia (UWA), a $499,411 Innovation Grant from the Future Health Research and Innovation (FHRI) Seed Fund to advance its proprietary MDMA Analogue Program. The FHRI Seed Fund provides Western Australian innovators with non-dilutive funding to facilitate projects with high commercial potential. This grant directly supports Emyria’s mission developing, applying and testing new therapies for mental health and selected neurodegenerative diseases. Initial funds will be used to progress a world-leading program targeting the enhancement of Parkinson’s disease treatment Associate Prof. Matt Piggott, a leading expert on MDMA-inspired drug discovery, will direct the medicinal chemistry and screening program Emyria CEO Michael Winlo said: “We are thrilled to receive this substantial grant from the West Australian Department of Health in partnership with UWA. This brings the amount of non-dilutive funding won this year to over $500k creating a significant boost for Emyria’s long-term innovation pipeline and, along with our MDMA-assisted therapy evaluation program, helps reinforce our global leadership in MDMA-related treatment delivery and development.” Read the ASX release 👉 https://lnkd.in/gNfYfyNb $EMD #EMD #Emyria #mentalhealth #research #innovation #grant

▪ PTSD Awareness Day - 27 June ▪ Did you know that Post-Traumatic Stress Disorder (PTSD) is the most common mental health disorder after depression? In Australia alone, an estimated 1.5 million people live with PTSD.  These figures are alarming, highlighting the urgent need for innovation in this space. At Emyria, we are reimagining PTSD treatment by providing comprehensive clinical services and support for those living with PTSD. We are also pioneering research into novel drug treatments, including our MDMA-assisted therapy program. We believe the future of PTSD treatment lies in integrating therapy and medication - and we are deeply committed to evidence-based research in both of these domains. Today we’re joining those raising awareness of PTSD and invite you to follow our journey.  $EMD #Emyria #mentalhealth #EMD #PTSD #MDMATherapyResearch #innovation #healthcare  #PTSDAwarenessDay

Emyria (ASX:EMD)  is pleased to announce its newly inaugurated Empax Centre has been selected for a groundbreaking clinical trial sponsored by New York-based Transcend Therapeutics. The Phase 2 trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen known for inducing neuroplasticity gene expression (promoting new nerve cell growth) in areas affected by PTSD, depression, and anxiety. Dr. Michael Winlo, CEO of Emyria, commented: “We are delighted to work with Transcend Therapeutics - a leader in neuropsychiatric innovation - on this exciting trial. Their approach complements our own dedication to mental health innovation and this study is a chance to utilise the full capabilities of our Empax Centre and unique skills of our team. We look forward to working with Transcend Therapeutics to improve mental health outcomes for patients with severe PTSD.” Read the ASX release 👉 https://lnkd.in/ggsWm4Ez $EMD #EMD #Emyria #mentalhealth #PTSD #clinicaltrial #neuroplasticity #innovation

📺 Grafa | Interview with Dr Michael Winlo #Emyria CEO and MD, Dr. Michael Winlo, recently recorded an interview with Heidi Cuthbert at Grafa discussing the Company's unique approach to mental health treatment, combining purpose-built clinics with drug development, to drive innovation and make a significant impact in the field.  Here’s an excerpt:   “What makes Australia really unique, and why businesses like ours have this opportunity is because Australia has created a legal access pathway to allow specially trained psychiatrists to be able to prescribe this treatment program for patients. It's quite challenging to get all of the approvals and navigate the regulatory system to get prepared and ready to deliver these treatments - but we've gone through all of that at Emyria, and now we are able to start evaluating these treatments with patients in the real world. Take a look 👉 https://lnkd.in/g-b6EiE8 $EMD #mentalhealth #EMD #PTSD #innovation #healthcare 

🎙 ASX Briefs Podcast This week, Emyria CEO Dr Michael Winlo made an appearance on ASX Briefs with Andrew Musgrave to discuss how Emyria’s unique combination of clinical services and innovative drug discovery pipeline is tackling critical gaps in mental health care. Here’s a snippet: “We have just opened up a brand new dedicated facility for the delivery and evaluation of psychedelic assisted treatments called the Empax Centre here in Perth. We believe this will be a flagship model for how these treatments can be delivered, commercially viable way, and importantly in a scalable way.”   Check it out 👉 https://lnkd.in/gzYxpr43 $EMD #EMD #Emyria #mentalhealth #healthcare #innovation #MDMATherapyResearch #PTSD

📺 Proactive Interview #Emyria CEO Michael Winlo spoke with Proactive’s Jonathan Jackson about the opening of The Empax Centre, Emyria's new cutting-edge facility aimed at enhancing mental health treatments, including MDMA-assisted therapy for PTSD. Michael spoke of the Company's vision for expansion, and the opportunity for more personalised treatments for patients under Emyria's unique therapeutic model. Take a look 👉 https://lnkd.in/g9gNzdjZ $EMD #EMD #Emyria #innovation #research #mentalhealth #PTSD #MDMAresearch #perth #healthcare